Barclays
ADCT icon

Barclays’s ADC Therapeutics ADCT Stock Holding History

Barclays’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
46,335
-115,051
-71% -$454K ﹤0.01% 3772
2025
Q4 		$570K Buy
161,386
+30,926
+24% +$125K ﹤0.01% 3770
2025
Q3 		$522K Sell
130,460
-14,947
-10% -$47.1K ﹤0.01% 3785
2025
Q2 		$390K Buy
145,407
+44,373
+44% +$93.3K ﹤0.01% 3898
2025
Q1 		$142K Sell
101,034
-40,461
-29% -$68.8K ﹤0.01% 4252
2024
Q4 		$282K Buy
141,495
+13,756
+11% +$36K ﹤0.01% 4145
2024
Q3 		$402K Buy
127,739
+93,890
+277% +$296K ﹤0.01% 3907
2024
Q2 		$107K Buy
+33,849
New +$135K ﹤0.01% 3873
2023
Q3 		– Sell
-314,925
Closed -$677K – 4578
2023
Q2 		$677K Sell
314,925
-19,347
-6% -$43.5K ﹤0.01% 2563
2023
Q1 		$652K Buy
+334,272
New +$1.23M ﹤0.01% 3071

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's ADCT Position: Q1 2026 in Review

Barclays reduced its ADC Therapeutics (ADCT) stake by 71% in Q1 2026, selling an estimated $454K and leaving 46,335 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #3772.

Barclays first reported a position in ADCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $677K in Q2 2023. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Barclays held 46,335 shares of ADC Therapeutics worth $174K as of Q1 2026.
  • Barclays sold 115,051 ADC Therapeutics shares in Q1 2026, an estimated $454K.
  • ADC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3772 holding.
  • Barclays first reported a position in ADC Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Barclays's ADC Therapeutics position peaked at $677K in Q2 2023.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.